The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Embecta ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

JMP Securities analyst Reni Benjamin maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...

Two names immediately came to mind: BeiGene and Legend Biotech. The companies share some similarities. Although not named in the BIOSECURE legislation, both firms have deep China links ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

BeiGene, Ltd. (ONC) shares rallied 8.9% in the last trading session to close at $200.99. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

BeiGene Ltd ( ($HK:6160) ) has issued an announcement. BeiGene Ltd., a biopharmaceutical company, announced the grant of share options and ...